A Study of COVID-19 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation
clinical trial to evaluate the safety, tolerability and preliminary immunogenicity of
COVID-19 mRNA Vaccine (SYS6006) in Chinese healthy adults aged 60 years and over.